XML 55 R46.htm IDEA: XBRL DOCUMENT v3.23.3
Acquisition of Pionyr Therapeutics - Summary of Estimated Fair Values of Assets Acquired and Liabilities Assumed (Details) - Pionyr Immunotherapeutics, Inc
$ in Thousands
Aug. 04, 2023
USD ($)
Assets Acquired  
Cash and cash equivalents $ 40,926
Marketable securities 20,362
Prepaid expenses and other current assets 1,359
Right-of-use-asset 3,889
Deposits and other assets 406
Total assets acquired 66,942
Liabilities Assumed  
Accounts payable (2,844)
Accrued expenses and other current liabilities (8,097)
Operating lease liability (1,485)
Long-term portion of operating lease liability (5,647)
Other long term liabilities (852)
Total liabilities assumed (18,925)
Net assets acquired $ 48,017 [1]
[1] (1) Net assets acquired does not include the remaining costs to complete the wind down of Pionyr development activities and operations.